PD52-02 FGFR3 MUTATIONS AND THEIR RELATION TO FGFR3 EXPRESSION AND CLINICAL OUTCOME IN A LARGE RADICAL CYSTECTOMY COHORT: IMPLICATIONS FOR ANTI-FGFR3 BLADDER CANCER TREATMENT?
Bas van Rhijn(The Netherlands Cancer Institute), T.C.M. Zuiverloon, Y. Neuzillet(Université de Versailles Saint-Quentin-en-Yvelines), Cheno Abas(Erasmus MC), S. A. Gotz(University of Regensburg), Annegien Broeks, Joyce Sanders(The Netherlands Cancer Institute), Yanish Scoorojebally, Deric van der Schoot(Amphia Ziekenhuis), Núria Malats(Spanish National Cancer Research Centre), Ellen C. Zwarthoff(Erasmus MC), Wolfgang Otto(University of Regensburg), Arndt Hartmann(Universitätsklinikum Erlangen), Roman Mayr(Ospedale di Bolzano), Mirari Márquez(Spanish National Cancer Research Centre), Theodorus van der Kwast(Erasmus MC), Francisco X. Real(Universitat Pompeu Fabra), Nanour Sirab(Centre National de la Recherche Scientifique), Damien Pouessel(Institut Claudius Regaud), Simone Bertz(Friedrich-Alexander-Universität Erlangen-Nürnberg), Joost L. Boormans(Erasmus MC), Markus Eckstein(Friedrich-Alexander-Universität Erlangen-Nürnberg), François Radvanyi(Centre National de la Recherche Scientifique), Peter J. Boström(University of Turku), Yves Allory(Institut Curie), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Geert van Leenders, Max M. Burger(Radboud University Nijmegen), Laura S. Mertens(Oncode Institute), Michael Jewett(Cancer Genomics Centre), Alexandre R. Zlotta(University of Toronto)
Cited by 0
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k